LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Pfizer

Uždarymo kaina

SektoriusSveikatos priežiūra

25.06 0.4

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.85

Max

25.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-45M

2.9B

Pardavimai

938M

15B

P/E

Sektoriaus vid.

13.302

35.724

Pelnas, tenkantis vienai akcijai

0.78

Dividendų pajamingumas

6.57

Pelno marža

19.982

Darbuotojai

81,000

EBITDA

266M

5.3B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+14.61% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

6.57%

3.09%

Kitas uždarbis

2025-10-28

Kitas dividendų mokėjimo data

2025-09-02

Kita Ex Dividend data

2025-11-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

9.2B

143B

Ankstesnė atidarymo kaina

24.66

Ankstesnė uždarymo kaina

25.06

Naujienos nuotaikos

By Acuity

35%

65%

152 / 372 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Pfizer Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-05 11:34; UTC

Uždarbis

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

2025-08-05 20:44; UTC

Uždarbis

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

2025-08-05 18:20; UTC

Uždarbis

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

2025-08-05 18:17; UTC

Uždarbis

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

2025-08-05 16:04; UTC

Rinkos pokalbiai

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

2025-08-05 15:25; UTC

Uždarbis

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

2025-08-05 13:56; UTC

Uždarbis

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

2025-08-05 11:43; UTC

Uždarbis

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

2025-08-05 11:27; UTC

Uždarbis

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

2025-08-05 10:57; UTC

Uždarbis

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

2025-08-05 10:55; UTC

Uždarbis

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

2025-08-05 10:53; UTC

Uždarbis

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

2025-08-05 10:51; UTC

Uždarbis

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

2025-08-05 10:50; UTC

Uždarbis

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

2025-08-05 10:49; UTC

Uždarbis

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

2025-08-05 10:49; UTC

Uždarbis

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

2025-08-05 10:48; UTC

Uždarbis

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

2025-08-05 10:48; UTC

Uždarbis

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

2025-08-05 10:47; UTC

Uždarbis

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

2025-08-05 10:46; UTC

Uždarbis

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

2025-08-05 10:45; UTC

Uždarbis

Pfizer Raises 2025 EPS Guidance >PFE

2025-08-05 10:45; UTC

Uždarbis

Pfizer 2Q EPS 51c >PFE

2025-08-05 10:45; UTC

Uždarbis

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

2025-08-05 10:45; UTC

Uždarbis

Pfizer 2Q Adj EPS 78c >PFE

2025-08-05 10:45; UTC

Uždarbis

Pfizer 2Q Rev $14.7B >PFE

2025-08-05 10:45; UTC

Uždarbis

Pfizer Sees FY Rev $61B-$64B >PFE

2025-08-04 15:26; UTC

Uždarbis

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

2025-07-30 18:36; UTC

Uždarbis

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

2025-07-09 09:17; UTC

Karštos akcijos

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

2025-06-10 12:18; UTC

Uždarbis

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Pfizer Prognozė

Kainos tikslas

By TipRanks

14.61% į viršų

12 mėnesių prognozė

Vidutinis 28.56 USD  14.61%

Aukščiausias 33 USD

Žemiausias 24 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pfizer kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

18 ratings

6

Pirkti

12

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

22.855 / 23.85Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

152 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.